Hengameh Shahidpoor, NP
Nurse Practitioner · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 23 years
- Graduated 2003
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Hengameh Shahidpoor’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$46,320
Medicare paid this office $46,320 for 323 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 96 | $16,044 | $142 |
| New patient visit (45+ min) | 94 | $11,474 | $122 |
| Return visit (30+ min) | 84 | $8,689 | $95 |
| New patient visit (30+ min) | 71 | $5,604 | $79 |
| Short return visit (20+ min) | 13 | $753 | $58 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of lower large bowel using a flexible endoscope | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
323 Original Medicare patients in 2024. Average age 77 · Women 57% · Also on Medicaid 6% · Health risk score 0.98. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 64% · Coronary heart disease 27% · Cancer 20% · Diabetes 18% · Chronic kidney disease 18% · Atrial fibrillation 17% · Depression 16% · Heart failure 10% · COPD 9% · Dementia 4% · Stroke 4%.
The office billed $191,302, Medicare allowed $63,189 and paid $46,320; for 402 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 323 | 402 | 77 | 0.98 | $191,302 | $46,320 |
| 2023 | 356 | 403 | 78 | 0.84 | $181,649 | $45,577 |
| 2022 | 322 | 398 | 77 | 0.88 | $179,602 | $46,412 |
| 2021 | 180 | 211 | 77 | 0.85 | $85,260 | $23,546 |
| 2020 | 142 | 158 | 77 | 0.97 | $51,399 | $12,303 |
| 2019 | 344 | 396 | 77 | 1.09 | $133,000 | $32,783 |
| 2018 | 378 | 460 | 75 | 0.99 | $164,001 | $40,745 |
| 2017 | 319 | 370 | 75 | 1.03 | $133,520 | $33,179 |
| 2016 | 288 | 342 | 74 | 1.02 | $132,318 | $34,147 |
| 2015 | 170 | 206 | 75 | 0.99 | $77,471 | $20,830 |
| 2014 | 157 | 219 | 71 | 1.23 | $35,190 | $13,489 |
| 2013 | 119 | 176 | 72 | 1.04 | $27,885 | $10,530 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 87 | $13,575 | $141 |
| New patient visit (45+ min) | 94 | $11,386 | $121 |
| New patient visit (30+ min) | 119 | $9,739 | $82 |
| Return visit (30+ min) | 64 | $6,917 | $105 |
2022: 6 services
| Long return visit (40+ min) | 114 | $17,389 | $136 |
| New patient visit (45+ min) | 88 | $11,052 | $126 |
| Return visit (30+ min) | 71 | $7,395 | $95 |
| New patient visit (60+ min) | 31 | $4,922 | $159 |
| New patient visit (30+ min) | 38 | $2,940 | $77 |
| Short return visit (20+ min) | 14 | $851 | $61 |
2021: 6 services
| Long return visit (40+ min) | 59 | $8,363 | $142 |
| Return visit (30+ min) | 54 | $5,315 | $95 |
| New patient visit (45+ min) | 32 | $4,030 | $126 |
| New patient visit (60+ min) | 13 | $2,293 | $176 |
| New patient visit (30+ min) | 17 | $1,489 | $88 |
| Short return visit (20+ min) | 15 | $999 | $67 |
2020: 4 services
| Return visit (30+ min) | 54 | $4,988 | $78 |
| New patient visit (45+ min) | 25 | $2,758 | $110 |
| Short return visit (20+ min) | 23 | $1,112 | $48 |
| New patient visit (15+ min) | 20 | $1,103 | $55 |
2019: 7 services
| Return visit (30+ min) | 141 | $12,021 | $82 |
| New patient visit (45+ min) | 51 | $6,100 | $120 |
| Short return visit (20+ min) | 84 | $4,877 | $55 |
| New patient visit (30+ min) | 41 | $3,132 | $76 |
| Biopsy of lower large bowel using a flexible endoscope | 11 | $2,529 | $230 |
| Long return visit (40+ min) | 16 | $1,770 | $111 |
| New patient visit (15+ min) | 28 | $1,430 | $51 |
2018: 7 services
| New patient visit (45+ min) | 112 | $13,579 | $121 |
| Return visit (30+ min) | 156 | $12,754 | $79 |
| Short return visit (20+ min) | 78 | $4,786 | $56 |
| New patient visit (30+ min) | 41 | $3,060 | $75 |
| Biopsy of lower large bowel using a flexible endoscope | 13 | $2,962 | $228 |
| Long return visit (40+ min) | 13 | $1,506 | $116 |
| New patient visit (15+ min) | 24 | $1,115 | $46 |
2017: 7 services
| Return visit (30+ min) | 139 | $11,399 | $78 |
| New patient visit (45+ min) | 78 | $9,115 | $117 |
| New patient visit (30+ min) | 48 | $3,622 | $75 |
| Short return visit (20+ min) | 47 | $2,997 | $58 |
| Biopsy of lower large bowel using a flexible endoscope | 11 | $2,465 | $224 |
| Long return visit (40+ min) | 11 | $1,092 | $99 |
| New patient visit (15+ min) | 12 | $726 | $60 |
2016: 3 services
| New patient visit (45+ min) | 142 | $16,843 | $119 |
| Return visit (30+ min) | 135 | $13,732 | $85 |
| New patient visit (30+ min) | 11 | $924 | $84 |
2015: 4 services
| New patient visit (45+ min) | 73 | $9,217 | $126 |
| Return visit (30+ min) | 73 | $7,317 | $86 |
| Long return visit (40+ min) | 13 | $1,495 | $115 |
| Short return visit (20+ min) | 15 | $1,094 | $58 |
2014: 4 services
| Return visit (30+ min) | 65 | $5,178 | $77 |
| Short return visit (20+ min) | 79 | $4,617 | $52 |
| New patient visit (45+ min) | 29 | $3,294 | $114 |
| Insertion of needle into vein for collection of blood sample | 23 | $76 | $3 |
2013: 4 services
| Return visit (30+ min) | 48 | $4,120 | $78 |
| Short return visit (20+ min) | 46 | $2,891 | $52 |
| New patient visit (45+ min) | 25 | $2,831 | $113 |
| Insertion of needle into vein for collection of blood sample | 27 | $89 | $3 |
Drugs they prescribed that Part D paid
$113,922
Pharmacies billed $113,922 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 647) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
510 generic and 137 brand-name prescriptions · $113,922 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 16 | $53,747 | $3,359 |
| Linzess | 49 | $31,791 | $649 |
| Sod Sulf-Potass Sulf-Mag Sulf | 87 | $5,682 | $65 |
| Budesonide Ec | 16 | $2,448 | $153 |
| Famotidine | 149 | $2,382 | $16 |
See all 11 drugs
| Creon | 16 | $53,747 | $3,359 |
| Linzess | 49 | $31,791 | $649 |
| Sod Sulf-Potass Sulf-Mag Sulf | 87 | $5,682 | $65 |
| Budesonide Ec | 16 | $2,448 | $153 |
| Famotidine | 149 | $2,382 | $16 |
| Cholestyramine | 17 | $1,307 | $77 |
| Sucralfate | 22 | $1,189 | $54 |
| Omeprazole | 127 | $1,150 | $9 |
| Pantoprazole | 46 | $952 | $21 |
| Gavilyte-C | 15 | $260 | $17 |
| Ondansetron Odt | 13 | $191 | $15 |
Year by year
| 2024 | 647 | 248 | 0% (0) | 21% | $113,922 |
| 2023 | 572 | 280 | 0% (0) | 24% | $78,154 |
| 2022 | 646 | 343 | 0% (0) | 35% | $106,383 |
| 2021 | 323 | 109 | 0% (0) | 16% | $48,196 |
| 2020 | 330 | 102 | 0% (0) | None | $56,444 |
| 2019 | 494 | 159 | 0% (0) | 14% | $144,295 |
| 2018 | 480 | 151 | 0% (0) | 16% | $506,759 |
| 2017 | 328 | 113 | 0% (0) | 11% | $32,154 |
| 2016 | 204 | 86 | 0% (0) | 14% | $13,388 |
| 2015 | 271 | 90 | 0% (0) | 22% | $20,738 |
| 2014 | 659 | 207 | 0% (0) | 30% | $51,705 |
| 2013 | 601 | 213 | 0% (0) | None | $43,781 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Linzess | 43 | $30,701 | $714 |
| Sod Sulf-Potass Sulf-Mag Sulf | 129 | $9,997 | $77 |
| Famotidine | 128 | $3,168 | $25 |
| Cholestyramine | 18 | $2,145 | $119 |
| Omeprazole | 98 | $1,301 | $13 |
| Gavilyte-C | 22 | $370 | $17 |
| Pantoprazole | 29 | $319 | $11 |
| Peg 3350-Electrolyte | 14 | $314 | $22 |
2022: 10 drugs
| Xifaxan | 16 | $35,359 | $2,210 |
| Linzess | 32 | $23,678 | $740 |
| Suprep | 81 | $9,249 | $114 |
| Sod Sulf-Potass Sulf-Mag Sulf | 82 | $6,675 | $81 |
| Famotidine | 163 | $3,515 | $22 |
| Budesonide Dr | 12 | $3,115 | $260 |
| Omeprazole | 65 | $1,231 | $19 |
| Pantoprazole | 44 | $748 | $17 |
| Peg 3350-Electrolyte | 28 | $524 | $19 |
| Gavilyte-C | 28 | $445 | $16 |
2021: 5 drugs
| Vemlidy | 11 | $14,759 | $1,342 |
| Linzess | 11 | $8,281 | $753 |
| Famotidine | 114 | $3,531 | $31 |
| Omeprazole | 58 | $1,124 | $19 |
| Pantoprazole | 59 | $976 | $17 |
2020: 5 drugs
| Linzess | 22 | $13,459 | $612 |
| Budesonide Ec | 19 | $4,043 | $213 |
| Famotidine | 95 | $2,779 | $29 |
| Pantoprazole | 67 | $1,124 | $17 |
| Omeprazole | 51 | $874 | $17 |
2019: 8 drugs
| Linzess | 20 | $12,039 | $602 |
| Budesonide Ec | 21 | $7,420 | $353 |
| Ranitidine | 103 | $1,719 | $17 |
| Pantoprazole | 107 | $1,310 | $12 |
| Omeprazole | 77 | $1,217 | $16 |
| Famotidine | 42 | $875 | $21 |
| Dicyclomine | 11 | $330 | $30 |
| Ondansetron Odt | 11 | $111 | $10 |
2018: 8 drugs
| Viread | 12 | $12,822 | $1,068 |
| Omeprazole | 121 | $1,659 | $14 |
| Suprep | 14 | $1,317 | $94 |
| Pantoprazole | 91 | $967 | $11 |
| Ranitidine | 63 | $724 | $11 |
| Sulfasalazine | 13 | $330 | $25 |
| Rabeprazole | 14 | $263 | $19 |
| Dicyclomine | 11 | $111 | $10 |
2017: 7 drugs
| Budesonide Ec | 16 | $8,765 | $548 |
| Omeprazole | 82 | $1,419 | $17 |
| Pantoprazole | 49 | $669 | $14 |
| Ranitidine | 34 | $578 | $17 |
| Sulfasalazine | 19 | $573 | $30 |
| Sucralfate | 13 | $318 | $24 |
| Dicyclomine | 13 | $186 | $14 |
2016: 5 drugs
| Omeprazole | 60 | $710 | $12 |
| Ranitidine | 26 | $386 | $15 |
| Pantoprazole | 25 | $385 | $15 |
| Sulfasalazine | 12 | $297 | $25 |
| Peg 3350-Electrolyte | 12 | $158 | $13 |
2015: 5 drugs
| Dexilant | 29 | $7,066 | $244 |
| Nexium | 17 | $5,329 | $313 |
| Omeprazole | 55 | $688 | $13 |
| Pantoprazole | 51 | $666 | $13 |
| Ranitidine | 61 | $388 | $6 |
2014: 10 drugs
| Nexium | 69 | $18,738 | $272 |
| Dexilant | 34 | $7,960 | $234 |
| Suprep | 56 | $4,437 | $79 |
| Rabeprazole | 16 | $1,663 | $104 |
| Omeprazole | 119 | $1,508 | $13 |
| Pantoprazole | 94 | $1,050 | $11 |
| Lansoprazole | 15 | $952 | $63 |
| Ranitidine | 108 | $856 | $8 |
| Dicyclomine | 38 | $374 | $10 |
| Polyethylene Glycol 3350 | 16 | $278 | $17 |
2013: 10 drugs
| Nexium | 50 | $12,057 | $241 |
| Suprep | 64 | $4,667 | $73 |
| Moviprep | 40 | $2,818 | $70 |
| Omeprazole | 114 | $2,020 | $18 |
| Dexilant | 11 | $1,811 | $165 |
| Pantoprazole | 60 | $916 | $15 |
| Ranitidine | 82 | $812 | $10 |
| Polyethylene Glycol 3350 | 37 | $776 | $21 |
| Dicyclomine | 33 | $526 | $16 |
| Metronidazole | 16 | $212 | $13 |
Money from drug and device companies
$238 in 2025
| 2025 | 3 | 9 | None | $238 |
| 2024 | 2 | 3 | None | $152 |
| 2023 | 1 | 3 | None | $137 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Creon | $136 | 6 payments
|
| Lilly USA | Omvoh | $68 | 2 payments
|
| Janssen Biotech | Tremfya | $34 | 1 payment
|
See all 9 published payments
| Abbvie | Meals · 2025-09-29 | Rinvoq | $27 |
| Abbvie | Meals · 2025-09-19 | None | $27 |
| Abbvie | Meals · 2025-09-05 | Creon | $31 |
| Lilly USA | Meals · 2025-07-14 | Omvoh | $35 |
| Abbvie | Meals · 2025-07-10 | Linzess | $8 |
| Janssen Biotech | Meals · 2025-06-27 | Tremfya | $34 |
| Lilly USA | Meals · 2025-06-24 | Omvoh | $33 |
| Abbvie | Meals · 2025-05-30 | Creon | $8 |
| Abbvie | Meals · 2025-03-13 | Creon | $35 |
See earlier years (2024, 2023)
2024: $152
| Lilly USA | Omvoh | $125 | 1 payment
|
| Abbvie | Creon | $27 | 2 payments
|
2023: $137
| Abbvie | Rinvoq | $137 | 3 payments
|
Professional record
- NPI
- 1508833856
- Licence
- CA NP23255, FL ARNP2751892
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-03-07
- NPI last updated
- 2020-05-28
- NPI record certified
- 2020-05-28
This is when the NPI record was last certified, not a medical board exam.